Press Releases

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead drug Metablok (LSALT peptide) to conduct a Phase II trial to prevent acute organ inflammation and injury experienced by patients with COVID-19.

Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

TORONTO, May 19, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has expanded the primary endpoint of the Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation and injury experienced by patients with COVID-19.

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has received a No Objection Letter from Health Canada to conduct a Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation experienced by patients with COVID-19.

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation

TORONTO, April 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has submitted a Clinical Trial Application to Health Canada for a Phase II human trial for its lead drug Metablok (LSALT peptide) to prevent lung and kidney inflammation in patients with COVID19.

Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model

TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today released a new video on its website showing the efficacy of its lead drug candidate Metablok in reducing neutrophil recruitment in a mouse model of lung inflammation.

Arch Biopartners Discloses New Patent Filing For Novel Drug Candidates To Prevent Lung Inflammation

TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “Lung Endothelial Binding Agents And Methods Of Use” to protect new drug candidates that reduce lung inflammation.

Arch Biopartners Safely Completes Expanded Dosing of METABLOK in Phase I Human Trial and Begins Focus on Phase II Trial

TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final eight healthy volunteers in its Phase I human trial of Metablok (LSALT peptide). This final group received the highest daily dose of Metablok tested to date for three consecutive days and met the primary endpoints of safety and tolerability.

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok (LSALT peptide) for future Phase II trials targeting inflammation in the lung, the kidney and/or the liver by adding a cohort of eight healthy volunteers to receive the highest daily dose tested to date for three consecutive days.

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0

TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Dr. Daniel Hassett’s team at the University of Cincinnati (UC) College of Medicine, and its collaborators, have published details regarding the efficacy of AB569 in killing various multidrug resistant bacteria.

Arch Biopartners Closes Convertible Note Financing

TORONTO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000 (the “Offering”).

The Note matures on February 1, 2025 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $0.89, in the thirty-day period prior to the maturity of the Note.